xequelbio_digital.jpg
Xequel Bio Announces Positive Results from Phase 1b Study of iNexin™, a Novel aCT1 Ophthalmic Solution
July 14, 2022 09:00 ET | Xequel Bio, Inc.
Excellent Safety and Tolerability Profile for iNexin™ for the Treatment of Corneal Injury Early Efficacy Signals Provide Rationale to Advance to Phase 2 Proprietary aCT1 Platform to Address Unmet...
LMAO logo.jpg
SeaStar Medical Announces Publication of Clinical Trial Results Demonstrating its SCD Significantly Lowered Mortality Rates among Critically Ill ICU COVID-19 Patients by Safely and Effectively Stopping Inflammation Causing Cytokine Storms
June 07, 2022 08:30 ET | LMF Acquisition Opportunities Inc.
DENVER, CO and TAMPA, FL, June 07, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical, a medical technology company developing a platform therapy to reduce the consequences of hyperinflammation on vital...
biomerica.png
Biomerica Reports 111% Increase in Q3 Fiscal 2022 Revenues to $7.6 million vs. Q3 Fiscal 2021
April 14, 2022 08:37 ET | Biomerica, Inc.
Q3 Net loss per share of $0.01 vs. a net loss of $0.18 per share from same period last year InFoods® IBS diagnostic-guided therapy clinical trial results demonstrated statistically significant...
ExCellThera_RGB.png
ExCellThera announces new data to be presented at the EBMT 2022 annual meeting
March 15, 2022 08:04 ET | ExCellThera
MONTRÉAL, March 15, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand...
biomerica.png
Biomerica Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome
February 08, 2022 06:39 ET | Biomerica, Inc.
InFoods® IBS Diagnostic-Guided Therapy is the first therapy of its kind using science, diet and technology to identify patient specific foods, which when eliminated, help reduce the symptoms of IBS...
ExCellThera_RGB.png
ExCellThera announces data to be presented at the American Society of Hematology 2021 annual meeting
November 29, 2021 08:05 ET | ExCellThera
MONTRÉAL, Nov. 29, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer...
biomerica.png
Biomerica expects Completion of Patient Enrollment for its InFoods® Diagnostic-Guided Therapy Irritable Bowel Syndrome Clinical Trial this week
August 30, 2021 08:19 ET | Biomerica, Inc.
Final patients to compete this double blinded trial by end of October. Top-Line trial results expected by year end.The InFoods® IBS Diagnostic-Guided Therapy is the first therapy of its kind for...
new-pharma300x111.jpg
Patients Rate their Clinical Trial Experience Positively, but Trial Locations Still Pose Barriers to Enrollment
July 27, 2021 09:00 ET | Informa Business Intelligence
NEW YORK, July 27, 2021 (GLOBE NEWSWIRE) -- Informa Pharma Intelligence, the global business intelligence provider for the biopharma industry, released its first “Patient Perspectives on Clinical...
hemostemix-logo-small.jpg
Hemostemix Announces Positive Results and Conclusions Reported in Phase II CLI Trial Abstract
October 21, 2019 08:30 ET | Hemostemix Inc.
CALGARY, Alberta, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company developing and commercializing...
ProQR logo1200x1200.png
ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients
October 10, 2019 06:00 ET | ProQR Therapeutics N.V.
Reported rapid, significant and durable improvements in vision at twelve monthsConcordant improvement in key secondary outcome measuresThe target registration dose of sepofarsen was well-tolerated...